USPTOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die US-Marke LEADERSHIP IN NANOPHARMACEUTICALS wurde als Wortmarke am 15.07.2010 beim Amerikanischen Patent- und Markenamt angemeldet. Der aktuelle Status der Marke ist "ABANDONED - NO STATEMENT OF USE FILED".
| Markenform | Wortmarke |
| Aktenzeichen | 85085203 |
| Anmeldedatum | 15. Juli 2010 |
| Veröffentlichungsdatum | 14. Dezember 2010 |
Markeninhaber
840 Memorial Drive, 5th Floor
02139 Cambridge
US
02139 Cambridge
US
Markenvertreter
Waren und Dienstleistungen
1
diagnostic and prognostic preparations for clinical or medical laboratory use; diagnostic and prognostic reagents for identifying a disease or disorder and/or the progression of a disease or disorder
5
Pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of pre-cancerous diseases or disorders; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of benign cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of inflammation and inflammatory diseases or disorders; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical preparations, namely, drug delivery systems that contain compounds which facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug delivery systems that contain nanometer scale or nanometer size compounds which facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug delivery systems that contain polymer and/or lipid based compounds for controlled release of a wide range of pharmaceuticals; pharmaceutical preparations for use in the diagnosis and prognosis of oncological diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of pre-cancerous diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis and treatment of benign cancers or neoplasms comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis and prognosis of malignant cancers or neoplasms comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of inflammation and inflammatory diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical; pharmaceutical preparations for use in the diagnosis, prognosis, and treatment of cardiovascular diseases or disorders comprising a pharmaceutical included with a nanometer-sized composition which facilitates the delivery and/or the controlled release of the pharmaceutical
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
ID: 1385085203